- Pharvaris (PHVS, Financial) will host a virtual R&D call on June 4, 2025, exploring deucrictibant's applications beyond hereditary angioedema (HAE) Type 1/2.
- The event will delve into bradykinin-mediated angioedema's pathophysiology, current treatment landscape, and unmet needs.
- Key speakers include experts from Amsterdam UMC and Pharvaris’ leadership team, including the CEO, CMO, and Chief Early Development Officer.
Pharvaris (PHVS), a late-stage biopharmaceutical company, has announced a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" scheduled for June 4, 2025, at 8:00 a.m. ET/14:00 CET. The focus will be on exploring the potential applications of their oral bradykinin B2 receptor antagonist, deucrictibant, beyond hereditary angioedema (HAE) Type 1/2.
The presentation aims to cover several key areas including the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment landscape, and existing unmet needs. Additionally, Pharvaris will present their biomarker approach for disease identification, highlighting innovative strategies in addressing bradykinin-mediated diseases.
Keynote speakers at the event include Dr. Danny M. Cohn from the Amsterdam UMC, alongside Pharvaris' senior management team: Dr. Anne Lesage, Chief Early Development Officer; Dr. Peng Lu, Chief Medical Officer; and Berndt Modig, CEO. Attendees can expect insights into ongoing research endeavors and future directions for deucrictibant's applications.
Interested parties can register for the live webcast through Pharvaris' website in the News and Events section. An archived replay of the event will be accessible for at least 30 days post-event, allowing stakeholders to revisit the discussions and insights shared.
For more information about Pharvaris and their ongoing developments, visit the company's website at https://pharvaris.com/.
